Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority

Executive Summary

The pivotal issue remaining for FDA's review of Boehringer Ingelheim's Pradaxa (dabigatran) is whether it will clear both the 110 mg and 150 mg doses and how it can craft labeling to guide appropriate use toward the higher dose, which seems likely to gain a superiority claim over warfarin.

You may also be interested in...



FDA’s Pradaxa Review Overemphasized Efficacy, Safety Experts Argue

Critique in the British Medical Journal of FDA’s review of Boehringer Ingelheim’s anticoagulant concludes agency should have approved a low-dose version, touching off a classic drug safety debate about the value of encouraging use of a potentially risky product.

BMJ’s Pradaxa Exposé Includes Wider Call For Monitoring Of All New Anticoagulants

British Medical Journal investigation focuses mainly on Boehringer’s direct thrombin inhibitor Pradaxa, but also suggests that all novel anticoagulants could benefit from testing to ensure the right anticoagulant dose is being given, for safety’s sake.

Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices

FDA’s decision to approve the 150 mg strength of Boehringer Ingelheim GmbH’s antithrombotic Pradaxa (dabigatran), but not the 110 mg dose, reflects agency doubts about the ability of risk management tools to change prescriber behavior that is likely to result in inappropriate use of a less effective dose.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel